Brown Brothers Harriman & Co’s Apellis Pharmaceuticals APLS Stock Holding History

Brown Brothers Harriman & Co’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-95	Closed	-$3.82K	–	1823
2026 Q1	$3.82K	Hold	95	–	–	﹤0.01%	1569
2025 Q4	$2.39K	Hold	95	–	–	﹤0.01%	1691
2025 Q3	$2.15K	Hold	95	–	–	﹤0.01%	1559
2025 Q2	$1.64K	Buy	+95	New	+$1.76K	﹤0.01%	1451

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Brown Brothers Harriman & Co's APLS Position: Q2 2026 in Review

Brown Brothers Harriman & Co sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 95 shares — an estimated $3.82K sold.

Brown Brothers Harriman & Co first reported a position in APLS in Q2 2025 and held it in 4 quarters. The position peaked at $3.82K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Brown Brothers Harriman & Co reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Brown Brothers Harriman & Co sold 95 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.82K.
Brown Brothers Harriman & Co first reported a position in Apellis Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Brown Brothers Harriman & Co's Apellis Pharmaceuticals position peaked at $3.82K in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.